Provided By GlobeNewswire
Last update: Aug 27, 2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences:
Read more at globenewswire.comNASDAQ:VTYX (12/2/2025, 12:18:07 PM)
8.213
-1.17 (-12.44%)
Find more stocks in the Stock Screener


